<DOC>
	<DOC>NCT00617604</DOC>
	<brief_summary>The purpose of this study is to determine whether alefacept is effective and well tolerated when used with a combination of tacrolimus, mycophenolate mofetil and steroids versus a combination therapy of placebo, tacrolimus and steroids in the prevention of kidney transplant rejection.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject with end stage kidney disease who is a suitable candidate for primary kidney transplantation or retransplantation Male or female subject at least 18 years of age and younger than 65 years Subject receiving a kidney transplant from a nonhuman leucocyte antigen (HLA) identical living donor or deceased HLA identical/nonHLA identical donor between 5 and 59 years of age with compatible ABO blood type (Blood group system A, B, AB and 0) Subject has a panel reactivity antibody grade &gt; 20% in the previous 6 months and/or had had a previous graft survival shorter than 1 year due to immunological reasons Subject received a kidney transplant from a nonheart beating donor Subject has received a kidney transplant from a 50 59 year old donor with two of the following three factors: history of hypertension, cerebrovascular accident as cause of death, final preprocurement serum creatinine &gt; 1.5 mg/dL (united network for organ sharing [UNOS] expanded criteria donor) Cold ischemia time of the donor kidney is â‰¥ 30 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>alefacept</keyword>
</DOC>